9,266 Shares in Cencora, Inc. (NYSE:COR) Acquired by Versor Investments LP

Versor Investments LP purchased a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 9,266 shares of the company's stock, valued at approximately $2,086,000.

Other hedge funds also recently made changes to their positions in the company. New Millennium Group LLC acquired a new stake in shares of Cencora in the second quarter valued at about $26,000. TCTC Holdings LLC bought a new stake in shares of Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the 1st quarter valued at approximately $30,000. MFA Wealth Advisors LLC bought a new position in shares of Cencora in the second quarter valued at $30,000. Finally, Concord Wealth Partners bought a new position in shares of Cencora in the third quarter valued at $30,000. 97.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on COR shares. Robert W. Baird increased their price target on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a report on Wednesday, August 21st. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday. Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $271.20.

Cencora Price Performance

Shares of NYSE COR traded up $0.68 during midday trading on Monday, reaching $249.09. The company's stock had a trading volume of 1,232,651 shares, compared to its average volume of 1,409,097. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.55 and a current ratio of 0.88. The company has a market cap of $49.08 billion, a P/E ratio of 33.17, a P/E/G ratio of 1.61 and a beta of 0.44. The business's 50 day moving average price is $231.95 and its two-hundred day moving average price is $230.74. Cencora, Inc. has a fifty-two week low of $191.11 and a fifty-two week high of $251.52.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.88%. Cencora's payout ratio is currently 27.16%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company's stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.